Edoxaban in Peripheral Arterial Disease
A phase 2 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 203 participants.
Also called NCT01802775
- Study
- In this atlas
Overview
- Design
- Interventional study; randomized; no masking; primary purpose treatment
- Phase
- Phase 2
- Enrolled
- 203 participants
- Sponsor
- Registry
-
NCT01802775 -
2012-003009-88
-
- Other papers using this trial's data
- Edoxaban Plus Aspirin vs Dual Antiplatelet Therapy in Endovascular Treatment of Patients With Peripheral Artery Disease: Results of the ePAD Trial
- Started
- (actual)
- Primary completion
- (actual)
- Completion
- (actual)
- Results first posted
- Countries
- United States, Austria, Belgium, Germany, Israel, Netherlands, Switzerland
- Registry status
- Completed
Technical summary
Registry record NCT01802775. Randomized; no masking; primary purpose treatment. Start 2013-02-06 (actual); primary completion 2014-12-03 (actual). Results posted on 2018-01-12.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- Edoxaban in Peripheral Arterial Disease
- Acronym
- ePAD
- Condition
- Peripheral Arterial Disease
- Intervention (Drug)
- edoxaban
- Intervention (Drug)
- Clopidogrel
- Intervention (Drug)
- Aspirin
- Lead sponsor
- Daiichi Sankyo
- Collaborator
- UMC Utrecht
Record details
- Record id
cardio:ct-nct01802775- Content hash
41aa659d65e9b0d701f904479122bcb8638f6e85f74558bdcf93e8345a34aff6